title: Expression of the h19 oncofetal gene in premalignant lesions of cervical cancer: a potential targeting approach for development of nonsurgical treatment of high-risk lesions.
abstract: Background. Recent data suggest a role for H19 gene in promoting cancer transformation and progression. Cervical cancer, progresses from high-grade lesions (CIN3). At present, it is unclear if CIN lesions express H19. Objectives. To determine H19 expression in patient samples of CIN3 as well as the ability of a construct in which the promoter from the H19 gene drives expression of the diphtheria toxin A chain (DTA) to inhibit cervical cancer cell growth in vitro. Methods. H19 transcript levels were evaluated on 10 biopsies of CIN3 using in situ hybridization. PCR was used to examine H19 expression in cervical cancer cell lines and in two samples from a patient with cervical carcinoma. Cell lines were transfected with H19-DTA to determine its impact on cell number. Results. H19 gene was expressed in the area of CIN3 in 9 out of 10 samples. RT-PCR indicated expression of H19 in cervical cancer samples and in one of the three cell lines examined. Transfection of all cell lines with H19-DTA vector resulted in inhibited cell growth. Conclusions. H19 is expressed in the majority of CIN3 samples. These results suggest that most CIN3 lesions could be targeted by H19-DTA. Further in vivo preclinical studies are thus warranted.
authors: Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Toronto, Princess Margaret Cancer Center, 610 University, Avenue M-700, Toronto, ON, Canada M5T 2M9.
authors: Tomer
authors: T
authors: Feigenberg
authors: Ofer N
authors: ON
authors: Gofrit
authors: Galina
authors: G
authors: Pizov
authors: Avraham
authors: A
authors: Hochberg
authors: Abraham
authors: A
authors: Benshushan
references: Oncogene. 2000 Nov 23;19(50):5810-6
references: 11126368
references: Int J Cancer. 2002 Apr 10;98(5):645-50
references: 11920631
references: J Urol. 2008 Dec;180(6):2379-83
references: 18950807
references: Cancer. 2008 Nov 15;113(10 Suppl):2981-94
references: 18980282
references: J Transl Med. 2009 Aug 06;7:69
references: 19656414
references: Mol Pathol. 2000 Dec;53(6):320-3
references: 11193051
references: Nature. 1995 May 4;375(6526):34-9
references: 7536897
references: Science. 1987 Dec 11;238(4833):1563-5
references: 3685993
references: PLoS One. 2007 Sep 05;2(9):e845
references: 17786216
references: Biochim Biophys Acta. 2002 Apr 24;1586(3):307-15
references: 11997082
references: Urology. 1995 Feb;45(2):335-8
references: 7855987
references: Oncogene. 1996 Jan 18;12(2):423-30
references: 8570220
references: Cancer Res. 2002 Nov 15;62(22):6442-6
references: 12438232
references: Mol Carcinog. 2002 Oct;35(2):63-74
references: 12325036
references: Annu Rev Biochem. 1992;61:331-54
references: 1497314
references: Mol Pathol. 1998 Feb;51(1):21-5
references: 9624415
references: Mol Ther. 2003 Apr;7(4):535-41
references: 12727117
references: Gynecol Oncol. 2008 Jul;110(1):37-42
references: 18433848
references: Nucleic Acids Res. 2001 Jan 1;29(1):189-93
references: 11125087
references: J Gene Med. 2005 Mar;7(3):366-74
references: 15521051
references: J Virol. 2003 Oct;77(19):10186-201
references: 12970404
references: Oncogene. 1997 Jul 10;15(2):169-77
references: 9244352